|
| Clinical observation of Tongbi Ⅰ in the treatment of rheumatoid arthritis |
| Hits 979 Download times 545 Received:February 25, 2021 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2021.08.13 |
| Key Words
rheumatoid arthritis;arthralgia syndrome;traditional Chinese medicine treatment;Tongbi Ⅰ |
| Author Name | Affiliation | | ZHENG Xinchun | Department of Rheumatology, Guanghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200050, China | | GE Gaoyue | Department of Rheumatology, Guanghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200050, China |
|
| Abstract
|
| [Objective] To observe the clinical efficacy and safety of Tongbi I in the treatment of rheumatoid arthritis.[Methods] A total of 80 patients with rheumatoid arthritis who were included in the outpatient department of Shanghai GuangHua Hospital from February 2018 to October 2019 were divided into the control group and the observationgroup according to the random number table method, with 40 patients in each group. The control group was treated with methotrexate tablets and meloxicam tablets, while the observation group was treated with Tongbi I, methotrexate tablets and meloxicam tablets. Patients in both groups were given a course of treatment for 12 weeks. The time of morning stiffness, number of joint tenderness, number of joint swelling, visual analogue scale (VAS), DAS28-ESR, DAS28-CRP, ESR, CRP and adverse reactions before and after treatment were compared between two groups to evaluate the clinical efficacy.[Results] After treatment, morning stiffness time, number of joint tenderness, number of joint swelling, VAS score, DAS28-ESR, DAS28-CRP, ESR and CRP of the two groups were all lower than those before treatment, and the differences were statistically significant (P<0.05). The improvement of morning stiffness time, number of joint tenderness, number of joint swelling, VAS score, DAS28-ESR and DAS28-CRP in the observation group was significantly better than that in the control group, and the difference was statistically significant(P<0.05), while the improvement of ESR and CRP was not statistically significant(P>0.05). No significant adverse reactions occurred in two groups.[Conclusion] TongbiⅠcombined treatment of rheumatoid arthritis is effective, which can significantly alleviate the clinical signs and symptoms of patients, the efficacy is better than the single methotrexate tablets, and no obvious adverse drug reactions. |
|
|
|
|
|
|
|
